Welcome to Paid Research Studies




  • Conditions:   Bleeding;   Platelet Dysfunction Due to Drugs;   Platelet Dysfunction
    Interventions:   Drug: Autologous Platelet Transfusion (room-temperature-stored);   Drug: Autologous Platelet Transfusion (cold-stored 5 days);   Drug: Autologous Platelet Transfusion (cold-stored 10 days);   Drug: Autologous Platelet Transfusion (cold-stored 15 days);   Drug: Aspirin;   Drug: Clopidogrel
    Sponsors:   Bloodworks;   National Blood Foundation
    Recruiting

  • Conditions:   Platelet Transfusion Refractoriness (PTR);   Thrombocytopenia
    Interventions:   Other: Platelet Transfusion - LONG Platelet Transfusion;   Other: Platelet Transfusion - SHORT Platelet Transfusion
    Sponsor:   National Institutes of Health Clinical Center (CC)
    Recruiting

  • Condition:   Heparin-induced Thrombocytopenia
    Intervention:   Procedure: Blood Draw
    Sponsors:   University of Arizona;   American College of Clinical Pharmacy
    Recruiting

  • Condition:   Heparin-induced Thrombocytopenia
    Intervention:   Procedure: Blood Draw
    Sponsors:   Vanderbilt University Medical Center;   American Heart Association
    Recruiting

  • Conditions:   Hematological Malignancies;   Thrombocytopenia
    Interventions:   Drug: EACA;   Other: Platelet transfusion
    Sponsor:   Emory University
    Recruiting

  • Condition:   Thrombocytopenia
    Interventions:   Drug: Tranexamic Acid;   Drug: Placebo
    Sponsors:   University of Washington;   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Condition:   Thrombotic Microangiopathies
    Intervention:   Drug: Defibrotide
    Sponsor:   University of California, San Francisco
    Recruiting

  • Conditions:   Polycythemia;   Thrombocytosis
    Intervention:  
    Sponsors:   University of Utah;   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Pediatric Cancer;   Thrombocytopenia;   Hemostatic Disorder;   Coagulation Defect; Acquired
    Interventions:   Drug: Tranexamic Acid;   Drug: Normal saline
    Sponsor:   Triulzi, Darrell, MD
    Recruiting

  • Conditions:   Thrombocytopenia;   Cirrhosis
    Intervention:   Device: TheraSphere® Yttrium-90 Glass Microspheres, BTG International Inc.
    Sponsors:   Northwestern University;   BTG International Inc.
    Recruiting

  • Condition:   Glanzmann Thrombasthenia
    Intervention:  
    Sponsors:   Rockefeller University;   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Hematologic Malignancies;   Hypoproliferative Thrombocytopenia
    Interventions:   Device: Mirasol platelets (MIR PLTs);   Device: Reference platelets (REF PLTs)
    Sponsors:   Terumo BCTbio;   Biomedical Advanced Research and Development Authority
    Recruiting

  • Condition:   Chemotherapy-induced Thrombocytopenia
    Interventions:   Drug: Avatrombopag;   Drug: Placebo Oral Tablet
    Sponsor:   Dova Pharmaceuticals
    Recruiting

  • Conditions:   Heparin-induced Thrombocytopenia;   Heparin-induced Thrombocytopenia and Thrombosis
    Intervention:   Drug: Apixaban
    Sponsors:   Massachusetts General Hospital;   Bristol-Myers Squibb
    Recruiting

  • Condition:   Purpura, Thrombocytopenic, Idiopathic
    Interventions:   Drug: BIVV009 6.5 grams;   Drug: BIVV009 7.5 grams
    Sponsor:   Bioverativ - a sanofi company
    Recruiting

  • Conditions:   Sepsis;   Thrombocytopenia
    Interventions:   Biological: Platelet transfusion;   Other: Saline
    Sponsor:   University of Kentucky
    Recruiting

  • Condition:   Immune Thrombocytopenia
    Intervention:  
    Sponsors:   Boston Children’s Hospital;   Sysmex America, Inc.;   Children's Hospital Colorado;   Children's Hospital of Philadelphia;   Texas Children's Hospital;   Columbia University;   Duke University
    Recruiting

  • Condition:   Von Willebrand Disease
    Interventions:   Biological: rVWF;   Biological: rFVIII
    Sponsors:   Baxalta now part of Shire;   Baxalta Innovations GmbH, now part of Shire
    Recruiting

  • Conditions:   Bone Marrow Failure Syndromes;   Erythrocyte Disorder;   Leukocyte Disorder;   Hemostasis;   Blood Coagulation Disorder;   Sickle Cell Disease;   Dyskeratosis Congenita;   Diamond-Blackfan Anemia;   Congenital Thrombocytopenia;   Severe Congenital Neutropenia;   Fanconi Anemia
    Intervention:  
    Sponsors:   St. Jude Children's Research Hospital;   Boston Children’s Hospital;   Baylor College of Medicine;   University of Memphis
    Recruiting

  • Conditions:   Bone Marrow Failure Syndrome;   Thalassemia;   Sickle Cell Disease;   Diamond Blackfan Anemia;   Acquired Neutropenia in Newborn;   Acquired Anemia Hemolytic;   Acquired Thrombocytopenia;   Hemophagocytic Lymphohistiocytoses;   Wiskott-Aldrich Syndrome;   Chronic Granulomatous Disease;   Common Variable Immunodeficiency;   X-linked Lymphoproliferative Disease;   Severe Combined Immunodeficiency;   Hurler Syndrome;   Mannosidosis;   Adrenoleukodystrophy
    Interventions:   Drug: Thiotepa--single daily dose;   Drug: Thiotepa--escalated dose
    Sponsors:   University of Florida;   Live Like Bella Pediatric Cancer Research
    Recruiting

  • Conditions:   Myeloproliferative Disorder;   Myeloproliferative Syndrome;   Myelofibrosis;   Polycythemia Vera;   Essential Thrombocythemia
    Interventions:   Other: USDA Diet;   Other: Mediterranean Diet
    Sponsor:   University of California, Irvine
    Recruiting

  • Conditions:   CALR Gene Mutation;   Essential Thrombocythemia;   JAK2 Gene Mutation;   MPL Gene Mutation;   Obstructive Sleep Apnea Syndrome;   Polycythemia Vera
    Interventions:   Procedure: Continuous Positive Airway Pressure;   Other: Patient Observation;   Other: Questionnaire Administration
    Sponsors:   University of Utah;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Sickle Cell Disease;   Transfusion Dependent Alpha- or Beta- Thalassemia;   Diamond Blackfan Anemia;   Paroxysmal Nocturnal Hemoglobinuria;   Glanzmann Thrombasthenia;   Severe Congenital Neutropenia;   Shwachman-Diamond Syndrome;   Non-Malignant Hematologic Disorders
    Interventions:   Drug: Reduced Toxicity Ablative Regimen;   Drug: Reduced Intensity Preparative Regimen;   Drug: Myeloablative Preparative Regimen
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Leukemia in Remission;   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Acute Myeloid Leukemia With FLT3/ITD Mutation;   Acute Myeloid Leukemia With Gene Mutations;   Aplastic Anemia;   B-Cell Non-Hodgkin Lymphoma;   CD40 Ligand Deficiency;   Chronic Granulomatous Disease;   Chronic Leukemia in Remission;   Chronic Lymphocytic Leukemia;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Congenital Amegakaryocytic Thrombocytopenia;   Congenital Neutropenia;   Congenital Pure Red Cell Aplasia;   Glanzmann Thrombasthenia;   Immunodeficiency Syndrome;   Myelodysplastic Syndrome;   Myelofibrosis;   Myeloproliferative Neoplasm;   Paroxysmal Nocturnal Hemoglobinuria;   Plasma Cell Myeloma;   Polycythemia Vera;   Recurrent Non-Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndrome;   Severe Aplastic Anemia;   Shwachman-Diamond Syndrome;   Sickle Cell Disease;   T-Cell Non-Hodgkin Lymphoma;   Thalassemia;   Waldenstrom Macroglobulinemia;   Wiskott-Aldrich Syndrome
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Procedure: Peripheral Blood Stem Cell Transplantation;   Radiation: Total-Body Irradiation
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Chronic Eosinophilic Leukemia, Not Otherwise Specified;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Dysplasia;   Essential Thrombocythemia;   FGFR1 Gene Rearrangement;   Myelodysplastic Syndrome;   Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Myeloid Neoplasm;   Myeloproliferative Neoplasm;   Myeloproliferative Neoplasm, Unclassifiable;   Overt Primary Myelofibrosis;   PDGFRA Gene Rearrangement;   PDGFRB Gene Rearrangement;   Polycythemia Vera;   Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase;   Prefibrotic/Early Primary Myelofibrosis
    Interventions:   Drug: Azacitidine;   Drug: Pevonedistat;   Drug: Venetoclax
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Primary Myelofibrosis;   Post-essential Thrombocythemia Myelofibrosis;   Post-polycythemia Vera Myelofibrosis;   Post ET MF;   Post PV MF
    Intervention:   Drug: AVID200
    Sponsors:   Icahn School of Medicine at Mount Sinai;   Formation Biologics;   National Cancer Institute (NCI);   Myeloproliferative Neoplasm Research Consortium (MPN-RC)
    Recruiting

  • Conditions:   Primary Myelofibrosis;   Post-essential Thrombocythemia Myelofibrosis;   Post-polycythemia Vera Myelofibrosis
    Intervention:   Drug: Selinexor
    Sponsors:   University of Utah;   Karyopharm Therapeutics Inc
    Recruiting

  • Conditions:   Bone Marrow Failure Syndrome;   Severe Aplastic Anemia;   Severe Congenital Neutropenia;   Amegakaryocytic Thrombocytopenia;   Diamond-Blackfan Anemia;   Schwachman Diamond Syndrome;   Primary Immunodeficiency Syndromes;   Acquired Immunodeficiency Syndromes;   Histiocytic Syndrome;   Familial Hemophagocytic Lymphocytosis;   Lymphohistiocytosis;   Macrophage Activation Syndrome;   Langerhans Cell Histiocytosis (LCH);   Hemoglobinopathies;   Sickle Cell Disease;   Sickle Cell-beta-thalassemia
    Intervention:   Biological: CD34 Stem Cell Selection Therapy
    Sponsor:   Diane George, MD
    Recruiting

  • Conditions:   Anemia;   ASXL1 Gene Mutation;   EZH2 Gene Mutation;   IDH1 Gene Mutation;   IDH2 Gene Mutation;   Plasma Cell Myeloma;   Primary Myelofibrosis;   Recurrent Plasma Cell Myeloma;   Secondary Myelofibrosis;   Thrombocytopenia
    Interventions:   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Procedure: Hematopoietic Cell Transplantation;   Other: Laboratory Biomarker Analysis
    Sponsor:   University of Utah
    Recruiting

  • Conditions:   Anemia;   B-Cell Prolymphocytic Leukemia;   Fatigue;   Fever;   Grade 1 Follicular Lymphoma;   Grade 2 Follicular Lymphoma;   Grade 3a Follicular Lymphoma;   Hairy Cell Leukemia;   Lymphadenopathy;   Lymphocytosis;   Lymphoplasmacytic Lymphoma;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma;   Night Sweats;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Small Lymphocytic Lymphoma;   Richter Syndrome;   Splenomegaly;   Thrombocytopenia;   Weight Loss
    Interventions:   Drug: Entospletinib;   Other: Laboratory Biomarker Analysis;   Biological: Obinutuzumab;   Other: Pharmacological Study
    Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Essential Thrombocythemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Juvenile Myelomonocytic Leukemia;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Polycythemia Vera;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Drug: Fludarabine phosphate;   Drug: Thiotepa;   Radiation: Total body irradiation;   Biological: Therapeutic allogeneic lymphocytes;   Drug: Cyclophosphamide;   Procedure: Allogeneic hematopoietic stem cell transplantation (HSCT);   Procedure: Peripheral blood stem cell transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Conditions:   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Myelofibrosis Transformation in Essential Thrombocythemia;   Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase;   Primary Myelofibrosis
    Interventions:   Drug: Azacitidine;   Other: Laboratory Biomarker Analysis;   Drug: Ruxolitinib Phosphate
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase;   Primary Myelofibrosis;   Secondary Myelofibrosis
    Interventions:   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration;   Drug: Smac Mimetic LCL161
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Aplastic Anemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Myelodysplastic Syndromes;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Essential Thrombocythemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Juvenile Myelomonocytic Leukemia;   Mastocytosis;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Polycythemia Vera;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Anemia;   Refractory Anemia With Ringed Sideroblasts;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Waldenström Macroglobulinemia
    Interventions:   Drug: Fludarabine;   Drug: Busulfan;   Radiation: Total Body Irradiation (TBI);   Biological: Donor Lymphocyte Infusion (DLI);   Drug: Cyclophosphamide (CY);   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Device: Allogeneic hematopoietic stem cell transplantation;   Procedure: Peripheral blood stem cell transplantation (PBSCT)
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Conditions:   Polycythemia Vera;   Essential Thrombocythemia;   Myelofibrosis
    Intervention:  
    Sponsors:   University of Utah;   Myeloproliferative Disorders-Research Consortium;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Pulmonary Fibrosis;   Healthy Volunteers;   Hermansky-Pudlak Syndrome (HPS)
    Intervention:  
    Sponsor:   National Human Genome Research Institute (NHGRI)
    Recruiting

  • Condition:   Hermansky-Pudlak Syndrome (HPS)
    Intervention:  
    Sponsor:   National Human Genome Research Institute (NHGRI)
    Recruiting

  • Conditions:   Thrombotic Microangiopathies;   Atypical Hemolytic Uremic Syndrome;   Multiple Organ Dysfunction Syndrome
    Intervention:   Drug: Eculizumab
    Sponsor:   Children's Hospital Medical Center, Cincinnati
    Recruiting

  • Conditions:   Thrombotic Microangiopathies;   Atypical Hemolytic Uremic Syndrome
    Intervention:   Biological: OMS721
    Sponsor:   Omeros Corporation
    Recruiting

  • Condition:   Thrombotic Thrombocytopenic Purpura
    Interventions:   Biological: Octaplas;   Drug: Standard Plasma
    Sponsor:   Octapharma
    Recruiting

  • Condition:   Heparin-induced Thrombocytopenia
    Interventions:   Drug: Danaparoid Sodium;   Drug: Argatroban
    Sponsor:   Aspen Global Incorporated
    Recruiting

  • Condition:   Immune Thrombocytopenia
    Interventions:   Drug: Eltrombopag;   Drug: Steroids;   Drug: IVIG;   Drug: Rho(D) Immune Globulin
    Sponsors:   Baylor College of Medicine;   Boston Children’s Hospital;   University of California, San Francisco
    Recruiting

  • Conditions:   Rare Disorders;   Undiagnosed Disorders;   Disorders of Unknown Prevalence;   Cornelia De Lange Syndrome;   Prenatal Benign Hypophosphatasia;   Perinatal Lethal Hypophosphatasia;   Odontohypophosphatasia;   Adult Hypophosphatasia;   Childhood-onset Hypophosphatasia;   Infantile Hypophosphatasia;   Hypophosphatasia;   Kabuki Syndrome;   Bohring-Opitz Syndrome;   Narcolepsy Without Cataplexy;   Narcolepsy-cataplexy;   Hypersomnolence Disorder;   Idiopathic Hypersomnia Without Long Sleep Time;   Idiopathic Hypersomnia With Long Sleep Time;   Idiopathic Hypersomnia;   Kleine-Levin Syndrome;   Kawasaki Disease;   Leiomyosarcoma;   Leiomyosarcoma of the Corpus Uteri;   Leiomyosarcoma of the Cervix Uteri;   Leiomyosarcoma of Small Intestine;   Acquired Myasthenia Gravis;   Addison Disease;   Hyperacusis (Hyperacousis);   Juvenile Myasthenia Gravis;   Transient Neonatal Myasthenia Gravis;   Williams Syndrome;   Lyme Disease;   Myasthenia Gravis;   Marinesco Sjogren Syndrome(Marinesco-Sjogren Syndrome);   Isolated Klippel-Feil Syndrome;   Frasier Syndrome;   Denys-Drash Syndrome;   Beckwith-Wiedemann Syndrome;   Emanuel Syndrome;   Isolated Aniridia;   Beckwith-Wiedemann Syndrome Due to Paternal Uniparental Disomy of Chromosome 11;   Beckwith-Wiedemann Syndrome Due to Imprinting Defect of 11p15;   Beckwith-Wiedemann Syndrome Due to 11p15 Translocation/Inversion;   Beckwith-Wiedemann Syndrome Due to 11p15 Microduplication;   Beckwith-Wiedemann Syndrome Due to 11p15 Microdeletion;   Axenfeld-Rieger Syndrome;   Aniridia-intellectual Disability Syndrome;   Aniridia - Renal Agenesis - Psychomotor Retardation;   Aniridia - Ptosis - Intellectual Disability - Familial Obesity;   Aniridia - Cerebellar Ataxia - Intellectual Disability;   Aniridia - Absent Patella;   Aniridia;   Peters Anomaly - Cataract;   Peters Anomaly;   Potocki-Shaffer Syndrome;   Silver-Russell Syndrome Due to Maternal Uniparental Disomy of Chromosome 11;   Silver-Russell Syndrome Due to Imprinting Defect of 11p15;   Silver-Russell Syndrome Due to 11p15 Microduplication;   Syndromic Aniridia;   WAGR Syndrome;   Wolf-Hirschhorn Syndrome;   4p16.3 Microduplication Syndrome;   4p Deletion Syndrome, Non-Wolf-Hirschhorn Syndrome;   Autosomal Recessive Stickler Syndrome;   Stickler Syndrome Type 2;   Stickler Syndrome Type 1;   Stickler Syndrome;   Mucolipidosis Type 4;   X-linked Spinocerebellar Ataxia Type 4;   X-linked Spinocerebellar Ataxia Type 3;   X-linked Intellectual Disability - Ataxia - Apraxia;   X-linked Progressive Cerebellar Ataxia;   X-linked Non Progressive Cerebellar Ataxia;   X-linked Cerebellar Ataxia;   Vitamin B12 Deficiency Ataxia;   Toxic Exposure Ataxia;   Unclassified Autosomal Dominant Spinocerebellar Ataxia;   Thyroid Antibody Ataxia;   Sporadic Adult-onset Ataxia of Unknown Etiology;   Spinocerebellar Ataxia With Oculomotor Anomaly;   Spinocerebellar Ataxia With Epilepsy;   Spinocerebellar Ataxia With Axonal Neuropathy Type 2;   Spinocerebellar Ataxia Type 8;   Spinocerebellar Ataxia Type 7;   Spinocerebellar Ataxia Type 6;   Spinocerebellar Ataxia Type 5;   Spinocerebellar Ataxia Type 4;   Spinocerebellar Ataxia Type 37;   Spinocerebellar Ataxia Type 36;   Spinocerebellar Ataxia Type 35;   Spinocerebellar Ataxia Type 34;   Spinocerebellar Ataxia Type 32;   Spinocerebellar Ataxia Type 31;   Spinocerebellar Ataxia Type 30;   Spinocerebellar Ataxia Type 3;   Spinocerebellar Ataxia Type 29;   Spinocerebellar Ataxia Type 28;   Spinocerebellar Ataxia Type 27;   Spinocerebellar Ataxia Type 26;   Spinocerebellar Ataxia Type 25;   Spinocerebellar Ataxia Type 23;   Spinocerebellar Ataxia Type 22;   Spinocerebellar Ataxia Type 21;   Spinocerebellar Ataxia Type 20;   Spinocerebellar Ataxia Type 2;   Spinocerebellar Ataxia Type 19/22;   Spinocerebellar Ataxia Type 18;   Spinocerebellar Ataxia Type 17;   Spinocerebellar Ataxia Type 16;   Spinocerebellar Ataxia Type 15/16;   Spinocerebellar Ataxia Type 14;   Spinocerebellar Ataxia Type 13;   Spinocerebellar Ataxia Type 12;   Spinocerebellar Ataxia Type 11;   Spinocerebellar Ataxia Type 10;   Spinocerebellar Ataxia Type 1 With Axonal Neuropathy;   Spinocerebellar Ataxia Type 1;   Spinocerebellar Ataxia - Unknown;   Spinocerebellar Ataxia - Dysmorphism;   Non Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature;   Spectrin-associated Autosomal Recessive Cerebellar Ataxia;   Spasticity-ataxia-gait Anomalies Syndrome;   Spastic Ataxia With Congenital Miosis;   Spastic Ataxia - Corneal Dystrophy;   Spastic Ataxia;   Rare Hereditary Ataxia;   Rare Ataxia;   Recessive Mitochondrial Ataxia Syndrome;   Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature;   Posterior Column Ataxia - Retinitis Pigmentosa;   Post-Stroke Ataxia;   Post-Head Injury Ataxia;   Post Vaccination Ataxia;   Polyneuropathy - Hearing Loss - Ataxia - Retinitis Pigmentosa - Cataract;   Muscular Atrophy - Ataxia - Retinitis Pigmentosa - Diabetes Mellitus;   Non-progressive Cerebellar Ataxia With Intellectual Disability;   Non-hereditary Degenerative Ataxia;   Paroxysmal Dystonic Choreathetosis With Episodic Ataxia and Spasticity;   Olivopontocerebellar Atrophy - Deafness;   NARP Syndrome;   Myoclonus - Cerebellar Ataxia - Deafness;   Multiple System Atrophy, Parkinsonian Type;   Multiple System Atrophy, Cerebellar Type;   Multiple System Atrophy;   Maternally-inherited Leigh Syndrome;   Machado-Joseph Disease Type 3;   Machado-Joseph Disease Type 2;   Machado-Joseph Disease Type 1;   Lethal Ataxia With Deafness and Optic Atrophy;   Leigh Syndrome;   Leukoencephalopathy With Mild Cerebellar Ataxia and White Matter Edema;   Leukoencephalopathy - Ataxia - Hypodontia - Hypomyelination;   Leigh Syndrome With Nephrotic Syndrome;   Leigh Syndrome With Leukodystrophy;   Leigh Syndrome With Cardiomyopathy;   Late-onset Ataxia With Dementia;   Intellectual Disability-hyperkinetic Movement-truncal Ataxia Syndrome;   Infection or Post Infection Ataxia;   Infantile-onset Autosomal Recessive Nonprogressive Cerebellar Ataxia;   Infantile Onset Spinocerebellar Ataxia;   GAD Ataxia;   Hereditary Episodic Ataxia;   Gliadin/Gluten Ataxia;   Friedreich Ataxia;   Fragile X-associated Tremor/Ataxia Syndrome;   Familial Paroxysmal Ataxia;   Exposure to Medications Ataxia;   Episodic Ataxia With Slurred Speech;   Episodic Ataxia Unknown Type;   Episodic Ataxia Type 7;   Episodic Ataxia Type 6;   Episodic Ataxia Type 5;   Episodic Ataxia Type 4;   Episodic Ataxia Type 3;   Episodic Ataxia Type 1;   Epilepsy and/or Ataxia With Myoclonus as Major Feature;   Early-onset Spastic Ataxia-neuropathy Syndrome;   Early-onset Progressive Neurodegeneration - Blindness - Ataxia - Spasticity;   Early-onset Cerebellar Ataxia With Retained Tendon Reflexes;   Early-onset Ataxia With Dementia;   Childhood-onset Autosomal Recessive Slowly Progressive Spinocerebellar Ataxia;   Dilated Cardiomyopathy With Ataxia;   Cataract - Ataxia - Deafness;   Cerebellar Ataxia, Cayman Type;   Cerebellar Ataxia With Peripheral Neuropathy;   Cerebellar Ataxia - Hypogonadism;   Cerebellar Ataxia - Ectodermal Dysplasia;   Cerebellar Ataxia - Areflexia - Pes Cavus - Optic Atrophy - Sensorineural Hearing Loss;   Brain Tumor Ataxia;   Brachydactyly - Nystagmus - Cerebellar Ataxia;   Benign Paroxysmal Tonic Upgaze of Childhood With Ataxia;   Autosomal Recessive Syndromic Cerebellar Ataxia;   Autosomal Recessive Spastic Ataxia With Leukoencephalopathy;   Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay;   Autosomal Recessive Spastic Ataxia - Optic Atrophy - Dysarthria;   Autosomal Recessive Spastic Ataxia;   Autosomal Recessive Metabolic Cerebellar Ataxia;   Autosomal Dominant Spinocerebellar Ataxia Due to Repeat Expansions That do Not Encode Polyglutamine;   Autosomal Recessive Ataxia, Beauce Type;   Autosomal Recessive Ataxia Due to Ubiquinone Deficiency;   Autosomal Recessive Ataxia Due to PEX10 Deficiency;   Autosomal Recessive Degenerative and Progressive Cerebellar Ataxia;   Autosomal Recessive Congenital Cerebellar Ataxia Due to MGLUR1 Deficiency;   Autosomal Recessive Congenital Cerebellar Ataxia Due to GRID2 Deficiency;   Autosomal Recessive Congenital Cerebellar Ataxia;   Autosomal Recessive Cerebellar Ataxia-pyramidal Signs-nystagmus-oculomotor Apraxia Syndrome;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to WWOX Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to TUD Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to KIAA0226 Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome;   Autosomal Recessive Cerebellar Ataxia With Late-onset Spasticity;   Autosomal Recessive Cerebellar Ataxia Due to STUB1 Deficiency;   Autosomal Recessive Cerebellar Ataxia Due to a DNA Repair Defect;   Autosomal Recessive Cerebellar Ataxia - Saccadic Intrusion;   Autosomal Recessive Cerebellar Ataxia - Psychomotor Retardation;   Autosomal Recessive Cerebellar Ataxia - Blindness - Deafness;   Autosomal Recessive Cerebellar Ataxia;   Autosomal Dominant Spinocerebellar Ataxia Due to a Polyglutamine Anomaly;   Autosomal Dominant Spinocerebellar Ataxia Due to a Point Mutation;   Autosomal Dominant Spinocerebellar Ataxia Due to a Channelopathy;   Autosomal Dominant Spastic Ataxia Type 1;   Autosomal Dominant Spastic Ataxia;   Autosomal Dominant Optic Atrophy;   Ataxia-telangiectasia Variant;   Ataxia-telangiectasia;   Autosomal Dominant Cerebellar Ataxia, Deafness and Narcolepsy;   Autosomal Dominant Cerebellar Ataxia Type 4;   Autosomal Dominant Cerebellar Ataxia Type 3;   Autosomal Dominant Cerebellar Ataxia Type 2;   Autosomal Dominant Cerebellar Ataxia Type 1;   Autosomal Dominant Cerebellar Ataxia;   Ataxia-telangiectasia-like Disorder;   Ataxia-intellectual Disability-oculomotor Apraxia-cerebellar Cysts Syndrome;   Ataxia-deafness-intellectual Disability Syndrome;   Ataxia With Vitamin E Deficiency;   Ataxia With Dementia;   Ataxia Neuropathy Spectrum;   Ataxia - Tapetoretinal Degeneration;   Ataxia - Photosensitivity - Short Stature;   Ataxia - Pancytopenia;   Ataxia - Oculomotor Apraxia Type 1;   Ataxia - Hypogonadism - Choroidal Dystrophy;   Ataxia - Other;   Ataxia - Genetic Diagnosis - Unknown;   Acquired Ataxia;   Adult-onset Autosomal Recessive Cerebellar Ataxia;   Alcohol Related Ataxia;   Multiple Endocrine Neoplasia;   Multiple Endocrine Neoplasia Type II;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2;   Multiple Endocrine Neoplasia, Type IV;   Multiple Endocrine Neoplasia, Type 3;   Multiple Endocrine Neoplasia (MEN) Syndrome;   Multiple Endocrine Neoplasia Type 2B;   Multiple Endocrine Neoplasia Type 2A;   Atypical Hemolytic Uremic Syndrome;   Atypical HUS;   Wiedemann-Steiner Syndrome;   Breast Implant-Associated Anaplastic Large Cell Lymphoma;   Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA);   Hemophagocytic Lymphohistiocytosis;   Behcet's Disease;   Alagille Syndrome;   Inclusion Body Myopathy With Early-onset Paget Disease and Frontotemporal Dementia (IBMPFD);   Lowe Syndrome;   Pitt Hopkins Syndrome;   1p36 Deletion Syndrome;   Jansen Type Metaphyseal Chondrodysplasia;   Cockayne Syndrome;   Chronic Recurrent Multifocal Osteomyelitis;   CRMO;   Malan Syndrome;   Hereditary Sensory and Autonomic Neuropathy Type Ie
    Intervention:  
    Sponsors:   Sanford Health;   National Ataxia Foundation;   International WAGR Syndrome Association;   4p- Support Group;   ML4 Foundation;   Cornelia de Lange Syndrome Foundation;   Stickler Involved People;   Kawasaki Disease Foundation;   Klippel-Feil Syndrome Alliance;   Klippel-Feil Syndrome Freedom;   Hyperacusis Research Limited;   Hypersomnia Foundation;   Kabuki Syndrome Network;   Kleine-Levin Syndrome Foundation;   Leiomyosarcoma Direct Research Foundation;   Marinesco-Sjogren Syndrome Support Group - NORD;   Mucolipidosis Type IV (ML4) Foundation;   People with Narcolepsy 4 People with Narcolepsy (PWN4PWN);   Soft Bones Incorporated;   American Multiple Endocrine Neoplasia Support;   Atypical Hemolytic Uremic Syndrome Foundation;   All Things Kabuki;   Wiedemann-Steiner Syndrome Foundation;   Breast Implant Victim Advocates;   PROS Foundation;   American Behcet's Disease Association
    Recruiting

  • Conditions:   Primary Myelofibrosis (PMF);   Post-Polycythemia Vera Myelofibrosis (Post-PV MF);   Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)
    Intervention:   Drug: PU-H71
    Sponsor:   Samus Therapeutics, Inc.
    Recruiting

  • Conditions:   Chronic Phase Myelofibrosis;   Primary Myelofibrosis;   Post-essential Thrombocythemia Myelofibrosis;   Polycythemia Vera
    Intervention:   Drug: Pembrolizumab
    Sponsors:   John Mascarenhas;   Massachusetts General Hospital;   Montefiore Medical Center
    Recruiting

  • Conditions:   Platelet Dysfunction;   Von Willebrand Diseases;   Healthy;   Congenital Platelets Abnormality
    Interventions:   Diagnostic Test: T-TAS 01 PL Chip;   Diagnostic Test: PFA-100 Col/Epi and Col/ADP
    Sponsors:   Hikari Dx, Inc.;   Fujimori Kogyo Co., Ltd.
    Recruiting

  • Condition:   Thrombotic Microangiopathies
    Intervention:   Biological: OMS721
    Sponsor:   Omeros Corporation
    Recruiting

  • Condition:   MPN (Myeloproliferative Neoplasms)
    Interventions:   Drug: Ruxolitinib;   Drug: Anagrelide;   Drug: Placebo
    Sponsor:   Incyte Corporation
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Blasts 20 Percent or More of Bone Marrow Nucleated Cells;   Blasts 5-19 Percent of Bone Marrow Nucleated Cells;   Blasts More Than 5 Percent of Bone Marrow Nucleated Cells;   Chronic Myelomonocytic Leukemia;   Essential Thrombocythemia;   Myelodysplastic/Myeloproliferative Neoplasm;   Myelofibrosis;   Philadelphia Chromosome Negative;   Polycythemia Vera;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
    Interventions:   Drug: Carboplatin;   Drug: Topotecan;   Drug: Topotecan Hydrochloride;   Drug: Veliparib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Hematologic Neoplasms;   Thrombocytopenia;   Anticoagulants;   Platelet Aggregation Inhibitors
    Interventions:   Drug: Hold;   Drug: Prophylactic dose antithrombotic;   Drug: Change antithrombotic Drug;   Biological: Change platelet transfusion threshold;   Drug: Full dose antithrombotics;   Device: Mechanical measures;   Drug: Intermediate dose antithrombotic
    Sponsor:   Maastricht University Medical Center
    Recruiting

  • Conditions:   Platelet Aggregation;   Nutritional and Metabolic Disease;   Cardiovascular Diseases
    Interventions:   Other: Oleocanthal-Rich Extra Virgin Olive Oil;   Other: Oleocanthal-low Extra Virgin Olive Oil
    Sponsor:   University of California, Davis
    Recruiting

  • Conditions:   Myelofibrosis;   Post-polycythemia Vera Myelofibrosis (PPV-MF);   Post-essential Thrombocythemia Myelofibrosis (PET-MF);   Primary Myelofibrosis (PMF)
    Intervention:   Drug: IMG-7289
    Sponsor:   Imago BioSciences,Inc.
    Recruiting

  • Conditions:   Chronic Kidney Diseases;   Heart Attack;   Stroke, Ischemic
    Interventions:   Drug: Ticagrelor 90mg;   Drug: Clopidogrel 75mg;   Drug: Aspirin 81 mg
    Sponsors:   University of Arkansas;   American Society of Nephrology
    Recruiting

  • Conditions:   Autoimmune Hemolytic Anemia;   Immune Thrombocytopenia
    Intervention:   Drug: KZR-616
    Sponsor:   Kezar Life Sciences, Inc.
    Recruiting

  • Condition:   Von Willebrand Disease
    Interventions:   Biological: von Willebrand factor (Recombinant);   Biological: Antihemophilic Factor (Recombinant)
    Sponsors:   Baxalta now part of Shire;   Baxalta Innovations GmbH, now part of Shire
    Recruiting

  • Condition:   Type 1 Von Willebrand Disease
    Interventions:   Drug: recombinant von Willebrand factor;   Drug: tranexamic acid
    Sponsors:   Margaret Ragni;   University of North Carolina;   Duke University
    Recruiting

  • Condition:   Von Willebrand Factor Deficiency
    Interventions:   Other: Genetic Analysis;   Other: Medical Record Data Abstraction;   Other: Pictorial Blood Assessment Chart (PBAC) score;   Other: Complete Bleeding Symptom ISTH Bleeding Assessment Tool
    Sponsors:   Baylor College of Medicine;   Texas Children's Hospital;   Shire
    Recruiting

  • Conditions:   Bleeding Disorder;   Ischemic Stroke;   Hemorrhagic Stroke;   Hematological Diseases;   Thrombocytopenia;   Coagulation Disorder;   Anemia;   Renal Insufficiency;   Coronary Artery Disease
    Interventions:   Device: XIENCE;   Drug: DAPT (aspirin and/or P2Y12 receptor inhibitor)
    Sponsor:   Abbott Medical Devices
    Recruiting

  • Conditions:   Primary Myelofibrosis;   Thrombocytosis
    Intervention:   Drug: FEDRATINIB
    Sponsors:   Celgene;   Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation
    Recruiting

  • Conditions:   Primary Myelofibrosis (PMF);   Post-Polycythemia Vera MF (Post-PV-MF);   Post-Essential Thrombocythemia MF (Post-ET-MF)
    Intervention:   Drug: KRT-232
    Sponsor:   Kartos Therapeutics, Inc.
    Recruiting

  • Condition:   Immune Thrombocytopenic Purpura
    Intervention:   Drug: PRN1008
    Sponsor:   Principia Biopharma Inc.
    Recruiting

  • Condition:   Atypical Hemolytic Uremic Syndrome (aHUS)
    Intervention:   Biological: ALXN1210
    Sponsor:   Alexion Pharmaceuticals
    Recruiting

  • Condition:   Hermansky Pudlak Syndrome
    Interventions:   Other: Pulmonary function test;   Other: Chest CT;   Other: Sample collection
    Sponsors:   Vanderbilt University;   University of South Florida;   National Institutes of Health (NIH);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Kaposiform Hemangioendothelioma (KHE);   Kasabach-Merritt Syndrome;   Tufted Angioma
    Interventions:   Drug: Vincristine;   Drug: Sirolimus
    Sponsors:   Boston Children’s Hospital;   Pfizer
    Recruiting

  • Condition:   Atypical Hemolytic-Uremic Syndrome
    Intervention:  
    Sponsors:   Alexion Pharmaceuticals;   Syneos Health
    Recruiting

  • Condition:   Immune Thrombocytopenic Purpura (ITP)
    Interventions:   Biological: Biological: M254;   Drug: Placebo;   Biological: Intravenous immunoglobulin (IVIg)
    Sponsor:   Momenta Pharmaceuticals, Inc.
    Recruiting

  • Condition:   Atherosclerotic Cardiovascular Disease
    Interventions:   Drug: Evolocumab;   Other: Placebo
    Sponsors:   University of Florida;   Amgen
    Recruiting

  • Condition:   Von Willebrand Diseases
    Intervention:   Drug: VWF-containing products
    Sponsor:   Octapharma
    Recruiting

  • Condition:   Immune Thrombocytopenic Purpura (ITP)
    Intervention:   Drug: eltrombopag
    Sponsor:   Novartis Pharmaceuticals
    Recruiting

  • Conditions:   Cardiovascular Diseases;   Platelet Aggregation, Spontaneous;   HIV/AIDS
    Intervention:   Diagnostic Test: Platelet aggregation
    Sponsor:   University of California, Los Angeles
    Recruiting

  • Conditions:   Head and Neck Disorder;   Free Flap
    Intervention:   Procedure: Platelet Rich Fibrin (PRF) Application
    Sponsor:   University of Florida
    Not yet recruiting

  • Conditions:   Coronary Artery Disease;   Atherosclerosis;   Stent Placement
    Interventions:   Drug: Dual Antiplatelet (DAPT) Therapy;   Device: The Synergy® stent
    Sponsors:   HonorHealth Research Institute;   Boston Scientific Corporation
    Recruiting

  • Conditions:   Thrombotic Thrombocytopenic Purpura;   Congenital Thrombotic Thrombocytopenic Purpura;   Familial Thrombotic Thrombocytopenic Purpura;   Thrombotic Thrombocytopenic Purpura, Congenital;   Upshaw-Schulman Syndrome
    Intervention:   Other: Observation
    Sponsors:   University Hospital Inselspital, Berne;   Swiss National Science Foundation;   Mach Gaensslen Foundation;   Baxalta Innovations GmbH, Wien, Austria
    Recruiting

  • Condition:   Coronary Artery Disease
    Interventions:   Drug: Clopidogrel;   Drug: Prasugrel;   Drug: ticagrelor;   Drug: aspirin;   Drug: rivaroxaban
    Sponsors:   University of Florida;   Janssen, LP
    Recruiting

  • Conditions:   Rheumatoid Arthritis;   Cardiovascular Diseases
    Interventions:   Drug: celecoxib 200mg capsule;   Drug: naproxen sodium 550mg tablet;   Drug: Aspirin 81mg tablet
    Sponsor:   Inova Health Care Services
    Recruiting

  • Conditions:   Dry Eye;   Graft-versus-host-disease;   Ocular Discomfort
    Interventions:   Biological: CAM-101 10%;   Biological: Vehicle Control;   Biological: CAM-101 30%
    Sponsors:   Cambium Medical Technologies LLC;   Massachusetts Eye and Ear Infirmary;   Oregon Health and Science University;   University of Michigan;   Duke University;   Stanford University;   University of Minnesota - Clinical and Translational Science Institute
    Recruiting